The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. BeOne Medicines Ltd.'s recent Forms 8-K announced quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in-licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
ONC affiliate files a Form 144 proposing the sale of 1,068 ADS. The filing states the ADS are related to Restricted Stock Vesting Under a Registered Plan and identifies Morgan Stanley Smith Barney LLC as the broker. The excerpt also lists recent ADS sales by Lai Wang: 1,169 ADS on 06/16/2026 (310,235.88), 756 ADS on 06/11/2026 (197,629.74), and 1,367 ADS on 06/08/2026 (368,246.83).
XIAOBIN WU reported sales of ADS (American Depositary Shares). The filing lists three ADS dispositions: 1,357 ADS for $361,996.85 on 06/16/2026, 626 ADS for $163,512.26 on 06/11/2026, and 1,484 ADS for $399,738.11 on 06/08/2026. The form also lists a separate ADS entry of 1,292 ADS tied to Restricted Stock Vesting Under a Registered Plan dated 06/22/2026.
ONC files a Form 144 to sell 3,410 ADS. The filing lists the sale as Restricted Stock Vesting Under a Registered Plan, with the issuer identified as the recipient of the vested ADS on 06/22/2026. The excerpt also reports three recent ADS dispositions by John Oyler: 4,940 ADS on 06/08/2026, 1,949 ADS on 06/11/2026, and 3,693 ADS on 06/16/2026, each showing corresponding gross proceeds.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported an open-market sale of 1,357 American Depositary Shares (ADS) at a weighted average price of $266.7626 per ADS. The footnotes state this sale was mandated by a tax withholding provision tied to the vesting of a restricted share unit (RSU) award previously granted to him.
Each ADS represents 13 ordinary shares. Following the transaction, Wu holds 12,365 ADS directly, 4,000 ADS indirectly through his wife, and 1,290,520 ordinary shares directly, indicating he retains a substantial equity position. The RSU award vests in four equal annual installments on each anniversary of June 15, 2023, with unvested units subject to accelerated vesting upon certain termination events.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported open‑market sales of 3,693 American Depositary Shares on June 16, 2026. The ADS were sold in three trades at weighted average prices of about $264.87 to $266.69 per ADS.
According to a footnote, these sales were executed under a mandatory tax‑withholding provision tied to the vesting of a restricted share unit award previously granted to him. After these transactions, Oyler directly holds 5,649,640 Ordinary Shares and also reports several indirect Ordinary Share holdings via trusts and an LLC, for some of which he disclaims beneficial ownership.
BeOne Medicines Ltd. executive Henry Lee Chan reported an automated sale of American Depositary Shares to satisfy tax obligations tied to restricted share unit vesting. He sold 590 American Depositary Shares at $265.975 each, representing 13 ordinary shares per ADS, and now directly holds 338,884 Ordinary Shares.
BeOne Medicines Ltd. executive Wang Lai reported a small mandatory share sale tied to equity compensation. On the date shown, he sold 1,169 American Depositary Shares at a weighted average price of $265.3857 per ADS to satisfy tax withholding on a vesting restricted share unit award, rather than as a discretionary trade. Each ADS represents 13 ordinary shares. After these transactions, he continues to hold 1,694,888 ordinary shares directly, while additional ordinary shares are held indirectly through Wang Holdings LLC and an employee RMB share participation plan, for which he disclaims beneficial ownership except for any pecuniary interest.
ONC proposes the sale of 590 ADSs under a registered plan vesting on 06/15/2026. The Form 144 lists the security as ADS and notes the disposition method as "Restricted Stock Vesting Under a Registered Plan." The filing also shows recent ADS dispositions by Chan Lee on 06/11/2026 (428 ADS, $110,267.78) and 06/08/2026 (871 ADS, $235,539.13), plus two trades of 332 ADS each on 05/13/2026 and 04/08/2026 with proceeds of $103,159.04 and $103,447.88.
ONC notice under Rule 144 reporting proposed sales of ADS and recent dispositions by a named holder. The filing lists an intended sale entry for ADS with a 06/15/2026 vesting/registered‑plan notation and two reported dispositions by Lai Wang on 06/08/2026 and 06/11/2026.
The record shows quantities reported next to those dates (1367 and 756) and references NASDAQ. This filing is administrative notice of resale under Rule 144; it does not state price or proceeds.
ONC submitted a Rule 144 notice reporting proposed sales of American Depositary Shares (ADS) by an affiliate. The filing lists a Restricted Stock Vesting Under a Registered Plan for 1,357 ADS on 06/15/2026 and two prior ADS dispositions by Xiaobin Wu on 06/11/2026 (626 ADS) and 06/08/2026 (1,484 ADS), with dollar amounts shown in the excerpt.